Table 4.
Adaptive choice reaction time test
| Reaction time (RT) at baseline (ms) | Maximum increase(ΔRTmax) of baseline-corrected RT (ms) | Time to reach ΔRTmax (min) | Area under effect curve (AUECRT) (ms × h) | Partial area under effect curve (AUECRT(0,120 min)) (ms × h) | |
|---|---|---|---|---|---|
| Midazolam i.v. | 575 ± 44 | 19 ± 22 | 120 (20–120) | 43 ± 84 | 22 ± 42 |
| Formulation 1 | 564 ± 45 | 16 ± 18 | 120 (20–240) | 4 ± 47 | 3 ± 31 |
| Formulation 2 | 548 ± 40 | 15 ± 16 | 70 (20–120) | 5 ± 77 | 15 ± 32 |
| Formulation 3 | 528 ± 32 | 19 ± 15 | 120 (20–120) | 38 ± 55 | 26 ± 25 |
| Formulation 4 | 519 ± 36 | 70 ± 39 | 20 (20–20) | 106 ± 81 | 85 ± 49 |
| Formulation 5 | 502 ± 42 | 95 ± 78* | 20 (20–120) | 183 ± 160** | 128 ± 102* |
Data are mean ± SD, except time to reach ΔRTmax which is given as median (range).
*
Significantly different (P < 0.01) from midazolam 1 mg i.v. and nasal 1 mg formulations 1, 2, and 3.
**
Significantly different (P < 0.05) from nasal 1 mg formulations 1, 2 and 3.